



## Company Announcement

### Nykode Therapeutics – Invitation to Q2 2025 Financial Results Presentation and Strategy Update

Oslo, Norway, August 20, 2025 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced it will release its second quarter 2025 financial results, including a strategy update, before the opening of financial markets on Wednesday, August 27, 2025.

The company will host a subsequent webcast presentation to review the financial and operating results. A question-and-answer session will follow.

#### Second Quarter 2025 Webcast:

Date: Wednesday, August 27, 2025

Time: 9 a.m. CET / 3 a.m. ET

Webcast: [https://event.webcasts.com/starthere.jsp?ei=1729435&tp\\_key=a1a96ff04c](https://event.webcasts.com/starthere.jsp?ei=1729435&tp_key=a1a96ff04c)

The financial report, as well as a live and archived webcast of the presentation, can be accessed in the Investors section of the company's website: <https://nykode.com/investors/financial-reports/>.

#### About Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic immunotherapy for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer. VB10.16 is currently being further developed in head and neck cancer. VB10.NEO, an individualized cancer neoantigen immunotherapy, has been investigated in two trials with more than 10 different indications.



Nykode is also utilizing its APC-targeted technology to create an immune tolerance platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at <http://www.nykode.com>.

**Contact:**

Alexandra Deschner, Head of IR  
Nykode Therapeutics ASA  
[IR@nykode.com](mailto:IR@nykode.com)

**Nykode Therapeutics ASA**

Oslo Science Park  
Gaustadalléen 21  
N-0349 Oslo, Norway

**Forward-looking statements for Nykode Therapeutics**

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.